Viatris Inc. Common Stock

Economic and market conditions · Economic recession and downturns

Current and changing economic conditions, including inflation, may adversely affect our industry, business, partners and suppliers. The global economy continues to experience significant volatility, and the economic environment may become less favorable.

Economic and market conditions · Market volatility and financial crises

The market price of our common stock has been and may continue to be volatile, and the value of your investment could materially decline. The price of Viatris' common stock has in the past and may continue to fluctuate materially from time to time.

Credit and liquidity · Credit risk and customer defaults

Viatris may be adversely affected by disruptions in the credit markets, including disruptions that reduce customers' access to credit and increase the costs to customers of obtaining credit. The credit markets have historically been volatile and therefore it is not possible to predict the ability of Viatris' customers to access short-term financing.

Market and investment · Market volatility and economic cycles

Viatris has certain material obligations relating to defined benefit pension and termination benefit programs. Viatris has certain material pension and post-employment benefit obligations associated with acquired businesses in both the U.S. and foreign countries.

Market and investment · Asset valuation and impairment

Charges to earnings resulting from acquisitions could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends or repurchase shares, and/or stock price. These and other future events or decisions have in the past and may in the future lead to significant asset impairments and/or related charges, including a goodwill impairment charge of $2.94 billion in 2025.

Tax and financial reporting · Financial reporting and accounting standards

There are inherent uncertainties involved in estimates, judgments and assumptions used in the preparation of financial statements in accordance with U.S. GAAP. Any future changes in estimates, judgments and assumptions used or necessary revisions to prior estimates, judgments or assumptions or changes in accounting standards could lead to a restatement or revision to previously issued financial statements.

Tax and financial reporting · Transfer pricing and international tax

If tax authorities determine that the intercompany pricing applied to our cross-border arrangements is inconsistent with the arms' length standard or otherwise ineffective, our tax liabilities could increase. We have potential tax exposures resulting from the varying application of statutes, regulations, and interpretations which include exposures on intercompany pricing of cross-border arrangements among our subsidiaries.

Legal and litigation · Litigation and legal proceedings

We are involved in various legal proceedings and certain government inquiries and may experience unfavorable outcomes of such proceedings or inquiries. We are or may be involved in various legal proceedings and certain government inquiries or investigations, including, but not limited to, patent infringement, product liability, personal injury, securities fraud, claims with respect to the manufacture, sale, marketing and distribution of opioid products, antitrust matters, breach of contract, consumer protection matters.

Legal and litigation · Intellectual property disputes

Our competitors, including branded pharmaceutical companies, and/or other third parties, may allege that we or our suppliers are infringing upon their intellectual property, including in an 'at risk launch' situation, which could result in substantial monetary damages, impact our ability to launch a product and/or our ability to continue marketing a product.

Industry regulation · Licensing and permits

For example, in December 2024 the FDA issued a warning letter and import alert related to our oral finished dose manufacturing facility in Indore, India. The warning letter and import alert restrict our ability to distribute certain products into the U.S. and have also negatively impacted our ability to sell products made at this facility to customers in other regions.

Data and privacy · Data protection and privacy laws

We are subject to federal, state and international data privacy and security laws and regulations governing the collection, use, disclosure, transmission and protection of personal information, including health-related information. As the legislative and regulatory landscape for data privacy and security continues to evolve around the world, there has been an increasing focus on data privacy and security matters that may affect our business.

Supply chain and procurement · Supplier operation and dependance

We have a limited number of manufacturing facilities and certain third-party suppliers produce a substantial portion of our API and products, some of which require a highly exacting and complex manufacturing process. A significant disruption at any facilities within our internal or third-party supply chain could impair our ability to produce and ship products to the market on a timely basis.

Human capital and workforce · Key personnel dependence and succession

In addition, while we work to ensure that we have effective plans in place for management succession throughout the organization, any anticipated or unanticipated management transition could create uncertainty, which could disrupt or result in changes to our strategy and have a negative impact on our business.

Strategic execution · Merger acquisition and divestiture risks

There are risks and uncertainties associated with divestitures, product rationalizations and asset sales, one or more of which could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends or repurchase shares, and/or stock price.

Customer and revenue · Reimbursement and pricing pressure healthcare or insurance

We have and may continue to experience pressure on the pricing of and reimbursements for certain of our products due to pricing controls, social or government pressure to lower the cost of drugs, and consolidation across the supply chain.

Customer and revenue · Changing customer preferences and behavior

Even if our products in development receive regulatory approval, such products may not achieve expected levels of market acceptance. Levels of market acceptance for our products could be impacted by several factors, including the availability, perceived advantages, and relative safety and efficacy of alternative products from our competitors.

Market position and competition · Patent expiration and generic competition

Many of our products are not protected by patent rights or have limited patent life and will soon lose patent protection. Loss of patent protection for a product typically is followed promptly with the launch of generic products. As a result, sales of many of these products decline or stop growing over time.

Corporate governance · Shareholder rights and activism

Provisions in the Viatris Charter and Viatris Bylaws and of applicable law may prevent or delay an acquisition of Viatris, which could decrease the trading price of Viatris common stock. The Viatris Charter, Viatris Bylaws and Delaware law contain provisions that may have the effect of deterring takeovers.

Corporate governance · Ethics and compliance culture

We are subject to the U.S. Foreign Corrupt Practices Act, U.S. Foreign Extortion Prevention Act, the U.K. Bribery Act, Chinese anti-corruption laws and similar worldwide anti-corruption laws, which impose restrictions on certain conduct and may carry substantial fines and penalties.

Corporate governance · Internal controls and risk management

We must maintain adequate internal controls and be able to provide an assertion as to the effectiveness of such controls on an annual basis. Effective internal controls are necessary for us to provide reasonable assurance with respect to our financial reports.